Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

By H. Meijers-Heijboer, A. V. D. van den Ouweland, J. Klijn, Marijke Wasielewski, Anja de Snoo, R. Oldenburg, A. Hollestelle, M. Houben, E. Crepin, M. V. van Veghel-Plandsoen and 31 more. Nature Genetics, 2002

980 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0cbc1b39d5d7424fdb404607295321273d465e94

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. D. Livingston
2. Barbara L. Weber
3. Sean V. Tavtigian
4. M. King

In Molecular Biology

1. Michael E. Cusick
2. David E. Hill
3. Marc Vidal
4. D. Livingston
5. Yosef Shiloh
6. Stephen B. Gruber
7. Sean V. Tavtigian
8. Jeffrey D. Parvin

Citations in the corpus

• RAD51 and Breast Cancer Susceptibility: No Evidence for Rare Variant Association in the Breast Cancer Family Registry Study (2012, background): “Background: Although inherited breast cancer has been associated with germline mutations in genes that are functionally involved in the DNA homologous recombination repair (HRR) pathway, including BRCA1, BRCA2, TP53, ATM, BRIP1, CHEK2 and PALB2, about 70% of breast cancer heritability remains unexpl”
• Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. (2006, background): “In contrast, inherited mutations in CHEK2 are less severe, leading to an approximately 2-fold increase in risk of breast cancer.(11-13) Previous evidence suggested that mutations in CHEK2 also increase risk for prostate and thyroid cancers.”
• ATM and related protein kinases: safeguarding genome integrity (2003, background): “Germline CHEK2 mutations have also been implicated in familial breast cance”
• Network modeling links breast cancer susceptibility and centrosome dysfunction. (2007, background): “and ATM and CHEK2 (both identified by low-penetrance mutations”
• BRCA1 and BRCA2: 1994 and beyond (2004, background): “, was found to confer a moderately increased risk of breast cancer in European”
• A compendium of mutational cancer driver genes (2020, neutral): “Primary (23,363;180) Metastasis (4,648;36) Relapse (65;5) Adult (25,277;173) Paediatric (2,799;48) 28,076 samples 66 cancer types 221 cohorts”